Phase II trial of temsirolimus alone and in combination with irinotecan forKRASmutant metastatic colorectal cancer: Outcome and results ofKRASmutational analysis in plasma

Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan

(2012) K.-L. G. Spindler et al.   CLINICAL CANCER RESEARCH

PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

(2011) F. Janku et al.   MOLECULAR CANCER THERAPEUTICS

Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis

(2010) Mohamed Bouchahda et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

All about KRAS for clinical oncology practice: Gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer

(2010) Helena Linardou et al.   CANCER TREATMENT REVIEWS

Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases

(2010) S. E. Baldus et al.   CLINICAL CANCER RESEARCH

Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: A meta-analysis of 22 studies

(2010) Li-Xin Qiu et al.   EUROPEAN JOURNAL OF CANCER

Circulating free tumor DNA and colorectal cancer

(2010) T. Lecomte et al.   GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE

Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab

(2010) Wendy De Roock et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

(2010) Federica Di Nicolantonio et al.   JOURNAL OF CLINICAL INVESTIGATION

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

mTOR Signaling Pathway Is a Target for the Treatment of Colorectal Cancer

(2009) Yan-Jie Zhang et al.   ANNALS OF SURGICAL ONCOLOGY

Marked Activity of Irinotecan and Rapamycin Combination toward Colon Cancer Cells In vivo and In vitro Is Mediated through Cooperative Modulation of the Mammalian Target of Rapamycin/Hypoxia-Inducible Factor-1  Axis

(2009) E. Pencreach et al.   CLINICAL CANCER RESEARCH

Detection of KRAS Oncogene in Peripheral Blood as a Predictor of the Response to Cetuximab Plus Chemotherapy in Patients with Metastatic Colorectal Cancer

(2009) L.-C. Yen et al.   CLINICAL CANCER RESEARCH

Targeted Inhibition of Mammalian Target of Rapamycin Signaling Inhibits Tumorigenesis of Colorectal Cancer

(2009) P. Gulhati et al.   CLINICAL CANCER RESEARCH

Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma

(2009) Sherif S. Farag et al.   LEUKEMIA RESEARCH

Evaluating Temsirolimus Activity in Multiple Tumors: A Review of Clinical Trials

(2009) Janet E. Dancey et al.   SEMINARS IN ONCOLOGY

Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs

(2008) R Bianco et al.   BRITISH JOURNAL OF CANCER

Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

(2008) Josep Tabernero et al.   JOURNAL OF CLINICAL ONCOLOGY